Cara Therapeutics (CARA) Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in NEJM streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
08.02.2023 - Publication underscores the importance of data in underrecognized neuropathic itch disorder which lacks an approved treatmentSTAMFORD, Conn., Feb. 08, 2023 (GLOBE NEWSWIRE) - Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage . Seite 1
During the open label trial, 57.1% of roflumilast-treated participants achieved Investigator Global Assessment (IGA) of clear or almost clear at any time.
Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.